• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Emulsifier-free, organotellurium-mediated living radical emulsion polymerization (emulsion TERP) of styrene: poly(dimethylaminoethyl methacrylate) macro-TERP agent?
  Yukiya Kitayama Polym. Chem., 2014,5, 2784-2792
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides 2-arylbenzofuran flavonoids 2-arylbenzofuran flavonoids
• Solvents and Organic Chemicals Organic Compounds Phenylpropanoids and polyketides 2-arylbenzofuran flavonoids
• Natural Products and Extracts Plant Extracts Plant based Faramea multiflora

Professional Introduction to 3',4-O-Dimethylcedrusin (CAS No. 166021-14-3)

3',4-O-Dimethylcedrusin, identified by the Chemical Abstracts Service Number (CAS No.) 166021-14-3, is a naturally occurring flavonoid derivative that has garnered significant attention in the field of pharmaceutical chemistry and biochemistry. This compound, isolated primarily from certain species of the genus *Cedrus*, exhibits a unique structural framework characterized by methoxylation at the 3' and 4' positions of the flavone core. Such structural modifications are known to modulate its biological activity, making it a subject of intense research interest.

The pharmacological properties of 3',4-O-Dimethylcedrusin have been extensively studied, particularly for its potential therapeutic applications. Flavonoids, as a class, are renowned for their antioxidant, anti-inflammatory, and antimicrobial properties. However, the methoxylation at specific positions in 3',4-O-Dimethylcedrusin enhances its bioavailability and target specificity, which are critical factors in drug design. Recent advancements in computational chemistry have allowed researchers to predict the binding affinities of this compound with various biological targets, including enzymes and receptors involved in metabolic pathways.

In recent years, 3',4-O-Dimethylcedrusin has been investigated for its role in modulating immune responses. Studies have demonstrated that this compound can interact with immune cells such as macrophages and T-lymphocytes, influencing cytokine production and apoptosis. These findings are particularly relevant in the context of developing immunomodulatory therapies for chronic inflammatory diseases. The structural analogs of 3',4-O-Dimethylcedrusin, such as those with varying degrees of methoxylation or additional functional groups, have been synthesized to explore structure-activity relationships (SAR) further.

The synthesis of 3',4-O-Dimethylcedrusin presents both challenges and opportunities. Traditional extraction methods from natural sources are labor-intensive and yield limited quantities. However, modern biotechnological approaches, including microbial fermentation and enzymatic biotransformation, offer promising alternatives for scalable production. These methods not only improve yield but also allow for the customization of the compound’s structure to enhance its pharmacological efficacy.

One of the most compelling aspects of 3',4-O-Dimethylcedrusin is its potential in oncology research. Preclinical studies have indicated that this compound can inhibit the proliferation of certain cancer cell lines by interfering with key signaling pathways such as MAPK and PI3K/Akt. The methoxylated flavonoids are particularly effective in inducing apoptosis in cancer cells while sparing normal cells, suggesting a high therapeutic index. This selective toxicity makes 3',4-O-Dimethylcedrusin an attractive candidate for further development into an anticancer drug.

The role of 3',4-O-Dimethylcedrusin in neuroprotection has also been explored recently. Oxidative stress and inflammation are hallmark features of neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease. Studies have shown that 3',4-O-Dimethylcedrusin can scavenge reactive oxygen species (ROS) and reduce inflammatory markers in neuronal cells. Additionally, its ability to cross the blood-brain barrier enhances its potential as a therapeutic agent for central nervous system disorders.

The regulatory landscape for compounds like 3',4-O-Dimethylcedrusin is evolving rapidly. As more research emerges on its safety and efficacy, regulatory agencies are updating guidelines to accommodate novel drug candidates derived from natural products. The use of computational modeling and high-throughput screening techniques has expedited the drug discovery process, allowing for faster translation from bench to bedside.

In conclusion, 3',4-O-Dimethylcedrusin (CAS No. 166021-14-3) represents a significant advancement in natural product-based drug development. Its unique structural features, coupled with promising preclinical data across multiple therapeutic areas, position it as a compound of great interest for future clinical investigations. As research continues to uncover new applications and synthetic pathways for this flavonoid derivative, it is likely to play an increasingly important role in modern medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)